{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rebelo de Almeida C"],"funding":["Howard Hughes Medical Institute"],"pagination":["299"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7286887"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(1)"],"pubmed_abstract":["Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending on the individual tumor, anti-VEGF therapies can either block or promote metastasis. In this context, an assay able to predict individual responses prior to treatment, including the impact on metastasis would prove of great value to guide treatment options. Here we show that zebrafish xenografts are able to reveal different responses to bevacizumab in just 4 days, evaluating not only individual tumor responses but also the impact on angiogenesis and micrometastasis. Importantly, we perform proo"],"journal":["Communications biology"],"pubmed_title":["Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy."],"pmcid":["PMC7286887"],"funding_grant_id":["MGF"],"pubmed_authors":["Nunes V","Gago J","Carvalho C","Mendes RV","Cardoso MJ","Alves A","Ribeiro J","Fior R","Cardoso F","Rebelo de Almeida C","Pezzarossa A","Brito MJ","Ferreira MG"],"additional_accession":[]},"is_claimable":false,"name":"Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.","description":"Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending on the individual tumor, anti-VEGF therapies can either block or promote metastasis. In this context, an assay able to predict individual responses prior to treatment, including the impact on metastasis would prove of great value to guide treatment options. Here we show that zebrafish xenografts are able to reveal different responses to bevacizumab in just 4 days, evaluating not only individual tumor responses but also the impact on angiogenesis and micrometastasis. Importantly, we perform proo","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-19T02:57:41.395Z","creation":"2020-06-25T07:28:32Z"},"accession":"S-EPMC7286887","cross_references":{"pubmed":["32523131"],"doi":["10.1038/s42003-020-1015-0"]}}